EpiBiologics develops antibody-based targeted therapies against membrane and extracellular proteins.
EpiBiologics has raised $107.0M in total funding. The most recent round was Series B. The last funding was announced in January 2026.
EpiBiologics's investors include Vivo Capital, Samsara BioCapital, Polaris Partners, Mission BioCapital, Digitalis Ventures.
EpiBiologics is headquartered in San Mateo, United States.
EpiBiologics develops antibody-based targeted therapies against membrane and extracellular proteins.
EpiBiologics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"EpiBiologics — Funding & Investors." VCBacked, January 8, 2026, https://www.vcbacked.co/company/epibiologics. Accessed July 21, 2026.
VCBacked. (2026). EpiBiologics — Funding & Investors. Retrieved July 21, 2026, from https://www.vcbacked.co/company/epibiologics
{{cite web |title=EpiBiologics — Funding & Investors |url=https://www.vcbacked.co/company/epibiologics |website=VCBacked |access-date=July 21, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated